Immunome
IMNM
182 hedge funds and large institutions have $2.54B invested in Immunome in 2025 Q4 according to their latest regulatory filings, with 50 funds opening new positions, 77 increasing their positions, 36 reducing their positions, and 20 closing their positions.
150% more first-time investments, than exits
New positions opened: 50 | Existing positions closed: 20
137% more capital invested
Capital invested by funds: $1.07B → $2.54B (+$1.47B)
114% more repeat investments, than reductions
Existing positions increased: 77 | Existing positions reduced: 36
25% more funds holding in top 10
Funds holding in top 10: 4 → 5 (+1)
24.05% more ownership
Funds ownership: 104.99% → 129.03% (+24%)
19% more funds holding
Funds holding: 153 → 182 (+29)
57% less call options, than puts
Call options by funds: $22.2M | Put options by funds: $51.7M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$87.8M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$61.3M |
| 3 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$52.8M |
| 4 |
JP Morgan Chase
New York
|
+$49.5M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$38.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$37.3M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
-$21.5M |
| 3 |
CM
Caption Management
Oklahoma City,
Oklahoma
|
-$18.2M |
| 4 |
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
|
-$12.1M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$6.36M |
IMNM Hedge Fund Activity: Q4 2025 in Review
182 of the 8,223 institutional investors tracked by Wall St. Rank reported a position in Immunome (IMNM) for Q4 2025, worth a combined $2.54B — up 137% from $1.07B a quarter earlier.
Buyers outnumbered sellers: 50 funds opened new IMNM positions and 20 closed out — a net gain of 30 holders — while 77 added to existing stakes and 36 trimmed.
The largest buyer was T. Rowe Price Investment Management, adding an estimated $87.8M. The largest seller was Opaleye Management, exiting entirely with an estimated $37.3M sold.
- 182 institutional investors held Immunome (IMNM) as of Q4 2025, up from 153 in Q3 2025.
- Funds reported $2.54B of Immunome stock for Q4 2025, up 137% quarter-over-quarter.
- 50 funds opened new Immunome positions in Q4 2025 and 20 closed out, a net change of +30 holders.
- The largest Immunome buyer in Q4 2025 was T. Rowe Price Investment Management, an estimated $87.8M added.
- The largest Immunome seller in Q4 2025 was Opaleye Management, an estimated $37.3M sold.
Based on aggregated 13F filings for Q4 2025.